Cyclacel Pharma (CYCC) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cyclacel Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 4:05 PM EDTÂ - Oral fadraciclib demonstrated good tolerability with continuous dosing;Â anticipate entering Phase 2 POC stage in 2H 2022
         - Demonstrated evidence of target engagement for CDK2 and CDK9
         - Company to host R&D day in fall of 2022 to highlight data updates          for fadraciclib and CYC140 in solid tumor Phase 1/2 studies
         - Cash runway into 2H 2023 -
               - Conference call scheduled for August 10, 2022 at 4:30 pm... More
